SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.
Artificial Intelligence Model Aims to Predict Best Options f... : Neurology Today lww.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lww.com Daily Mail and Mail on Sunday newspapers.
MRFF backs Monash health and medical research with $28M in funding miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
An Artificial Intelligence (AI) model has been shown to have the capacity to forecast the best personalized anti-seizure medicine for individuals with recently diagnosed epilepsy, according to a Monash University-led study, believed to be the first in the world.